MSC Therapy for Chronic Kidney Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing the safety of injecting special cells called mesenchymal stem cells into the bloodstream of patients with long-term kidney disease. The goal is to see if these cells can help repair and heal damaged kidneys. The study will use two different doses to find the best approach. Mesenchymal stem cells (MSCs) have been investigated in numerous studies for their potential to repair kidney injury and improve renal function.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, it mentions that participants should be on the maximally tolerated dose of certain medications for kidney disease and diabetes, suggesting you may need to continue those.
Is MSC therapy safe for humans?
Studies show that adipose-derived mesenchymal stem cell (MSC) therapy is generally safe, with no significant cellular or renal toxicity observed in short-term studies. However, there is a report of potential kidney damage in a chronic kidney disease patient after autologous MSC therapy, highlighting the need for caution.12345
How is the treatment with allogeneic adipose-derived mesenchymal stem cells different from other treatments for chronic kidney disease?
This treatment is unique because it uses stem cells from fat tissue, which have anti-inflammatory properties and can help repair kidney damage, unlike traditional treatments that mainly focus on managing symptoms. It offers a new approach by potentially regenerating kidney tissue and improving kidney function.678910
What data supports the effectiveness of the treatment Allogeneic adipose-derived mesenchymal stem cells (MSC) for chronic kidney disease?
Research shows that adipose-derived mesenchymal stem cells (MSCs) can reduce kidney damage and improve kidney function in animal models of chronic kidney disease. These cells have anti-inflammatory properties and can help modulate the immune response, which may be beneficial in treating kidney diseases.2691011
Who Is on the Research Team?
LaTonya Hickson, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
Adults aged 30-80 with chronic kidney disease, having specific levels of kidney function and protein in urine despite certain medications, can join. They must be able to consent and not have severe anemia, recent heart issues, liver cirrhosis, or a history of significant infections like hepatitis B/C or HIV. Pregnant individuals or those unwilling to use contraception post-treatment are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) in one of two dosing regimens: two intravenous infusions of 100x10^6 cells at time zero and three months, or a single intravenous infusion of 200x10^6 cells
Follow-up
Participants are monitored for safety and effectiveness after treatment, including adverse events and changes in eGFR
What Are the Treatments Tested in This Trial?
Interventions
- Allogeneic adipose-derived mesenchymal stem cells (MSC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
LaTonya J. Hickson
Lead Sponsor